Dicerna Pharmaceuticals Inc
DRNA evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Lead Asset:
- belcesiran (Phase 2)
What it means
What to watch
Prepared research question
What matters most for DRNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 8 clinical trials for Dicerna Pharmaceuticals Inc.
Run Dicerna Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dicerna Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Dicerna Pharmaceuticals Inc's lead drug candidate?
Dicerna Pharmaceuticals Inc's most advanced tracked candidate is belcesiran (Phase 2) for Alpha 1-Antitrypsin Deficiency.
Who is the CEO of Dicerna Pharmaceuticals Inc?
Massachusetts April is the chief executive officer of Dicerna Pharmaceuticals Inc (DRNA).
What therapeutic areas does Dicerna Pharmaceuticals Inc focus on?
Dicerna Pharmaceuticals Inc develops therapies across Oncology, Infectious Disease, Dermatology, Nephrology, Gastroenterology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.